Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| LA JOLLA PHARMACEUTICAL COLJPC · Entity 124310 | Chief Medical Officer | July 01, 2020 | September 17, 2020 |
| REVELATION BIOSCIENCES, INC.REVB · Entity 8359 | Director | August 17, 2026 | August 18, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
LA JOLLA PHARMACEUTICAL CO
Report date July 01, 2020 · Filed September 17, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 13,447 |
Reported balance
After 2020-09-15 transaction · row 1
1 source rowRow 1 · 2020-09-15 · Grant · Acquired 286 · Balance 13,447 F1: These shares were acquired on 09/15/2020 through the La Jolla Pharmaceutical Company 2018 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.53 · Expires 2030-09-15 | Direct | 286 |
Reported balance
After 2020-09-15 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2020-09-15 · Grant · Acquired 286 · Balance 286 F2: The stock options vest and become exercisable with respect to 25% of the underlying shares on the one-year anniversary of grant date and then vest and become exercisable ratably on a monthly basis over the next three years. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.52 · Expires 2030-07-01 | Direct | 60,000 |
Reported balance
After 2020-07-01 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2020-07-01 · Grant · Acquired 60,000 · Balance 60,000 F2: The stock options vest and become exercisable with respect to 25% of the underlying shares on the one-year anniversary of grant date and then vest and become exercisable ratably on a monthly basis over the next three years. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares were acquired on 09/15/2020 through the La Jolla Pharmaceutical Company 2018 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c).
F2: The stock options vest and become exercisable with respect to 25% of the underlying shares on the one-year anniversary of grant date and then vest and become exercisable ratably on a monthly basis over the next three years.
REVELATION BIOSCIENCES, INC.
Report date August 17, 2026 · Filed August 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 44,169 |
Reported balance
After 2026-08-17 transaction · row 1
1 source rowRow 1 · 2026-08-17 · Grant · Acquired 32,011 · Balance 44,169 F1: These shares are subject to a restricted stock award granted under the Revelation Biosciences, Inc. 2021 Equity Incentive Plan, with 50% of the shares vesting on the two-year anniversary of the grant date, and the remaining 50% of the shares vesting on the four-year anniversary of the grant date, provided that the Reporting Person remains continuously employed by or provides services to the Company or any subsidiary through the applicable vesting date; and provided, further that such vesting could be accelerated upon the achievement of certain performance milestones. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares are subject to a restricted stock award granted under the Revelation Biosciences, Inc. 2021 Equity Incentive Plan, with 50% of the shares vesting on the two-year anniversary of the grant date, and the remaining 50% of the shares vesting on the four-year anniversary of the grant date, provided that the Reporting Person remains continuously employed by or provides services to the Company or any subsidiary through the applicable vesting date; and provided, further that such vesting could be accelerated upon the achievement of certain performance milestones.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 15, 2018 Filed Nov 19, 2018 17:04 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantStock Option (Right to Buy) · Derivative | 16 | $0.00 Strike: $14.90 | $0.00 |
DisclosureSEC source: 0000920465-18-000055 · wf-form4_154266508013411.xml · derivative · entry 2 Chawla Lakhmir S · CIK 0001646626 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16 Underlying: Common Stock · 16 shares Expires 2028-11-15 F2 · derivative.exercise_date: The stock option vests and becomes exercisable with respect to 25% of the underlying shares on the one-year anniversary of grant date and then vests and becomes exercisable ratably on a monthly basis over the next three years. Read SEC document |
| November 15, 2018 Filed Nov 19, 2018 17:04 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantCommon Stock | 16 | $12.67 | $202.64 |
DisclosureSEC source: 0000920465-18-000055 · wf-form4_154266508013411.xml · nonDerivative · entry 1 Chawla Lakhmir S · CIK 0001646626 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,131 F1 · kind: These shares were acquired on 11/15/2018 through the La Jolla Pharmaceutical Company 2018 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| October 31, 2018 Filed Nov 1, 2018 20:42 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantStock Option (Right to Buy) · Derivative | 15 | $0.00 Strike: $16.30 | $0.00 |
DisclosureSEC source: 0000920465-18-000052 · wf-form4_154111930710574.xml · derivative · entry 2 Chawla Lakhmir S · CIK 0001646626 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15 Underlying: Common Stock · 15 shares Expires 2028-10-31 F2 · derivative.exercise_date: The stock option vests and becomes exercisable with respect to 25% of the underlying shares on the one-year anniversary of grant date and then vests and becomes exercisable ratably on a monthly basis over the next three years. Read SEC document |
| October 31, 2018 Filed Nov 1, 2018 20:42 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantCommon Stock | 15 | $13.86 | $207.83 |
DisclosureSEC source: 0000920465-18-000052 · wf-form4_154111930710574.xml · nonDerivative · entry 1 Chawla Lakhmir S · CIK 0001646626 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,115 F1 · kind: These shares were acquired on 10/31/2018 through the La Jolla Pharmaceutical Company 2018 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| October 15, 2018 Filed Oct 15, 2018 20:53 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantStock Option (Right to Buy) · Derivative | 15 | $0.00 Strike: $16.25 | $0.00 |
DisclosureSEC source: 0000920465-18-000042 · wf-form4_153965118132194.xml · derivative · entry 2 Chawla Lakhmir S · CIK 0001646626 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15 Underlying: Common Stock · 15 shares Expires 2028-10-15 F2 · derivative.exercise_date: The stock option vests and becomes exercisable with respect to 25% of the underlying shares on the one-year anniversary of grant date and then vests and becomes exercisable ratably on a monthly basis over the next three years. Read SEC document |
| October 15, 2018 Filed Oct 15, 2018 20:53 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantCommon Stock | 15 | $13.81 | $207.15 |
DisclosureSEC source: 0000920465-18-000042 · wf-form4_153965118132194.xml · nonDerivative · entry 1 Chawla Lakhmir S · CIK 0001646626 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,100 F1 · kind: These shares were acquired on 10/15/2018 through the La Jolla Pharmaceutical Company 2018 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| December 27, 2017 Filed Dec 29, 2017 17:04 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantStock Option (Right to Buy) · Derivative | 6,700 | $0.00 Strike: $32.47 | $0.00 |
DisclosureSEC source: 0000920465-17-000092 · wf-form4_151458508417039.xml · derivative · entry 1 Chawla Lakhmir S · CIK 0001646626 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,700 Underlying: Common Stock · 6,700 shares Expires 2027-12-27 F1 · derivative.exercise_date: The stock option vests and becomes exercisable with respect to 25% of the underlying shares on the one-year anniversary of grant date and then vests and becomes exercisable ratably on a monthly basis over the next three years. Read SEC document |
| December 11, 2017 Filed Dec 13, 2017 21:05 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantStock Option (Right to Buy) · Derivative | 49,000 | $0.00 Strike: $28.10 | $0.00 |
DisclosureSEC source: 0000920465-17-000076 · wf-form4_151321710415821.xml · derivative · entry 1 Chawla Lakhmir S · CIK 0001646626 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,000 Underlying: Common Stock · 49,000 shares Expires 2027-12-11 F1 · derivative.exercise_date: The stock option vests and becomes exercisable with respect to 25% of the underlying shares on the one-year anniversary of grant date and then vests and becomes exercisable ratably on a monthly basis over the next three years. Read SEC document |
| March 03, 2017 Filed Mar 6, 2017 16:01 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | PurchaseCommon Stock | 1,000 | $34.48 | $34,479.90 |
DisclosureSEC source: 0000920465-17-000035 · wf-form4_148883408805069.xml · nonDerivative · entry 2 Chawla Lakhmir S · CIK 0001646626 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,085 Read SEC document |
| March 02, 2017 Filed Mar 6, 2017 16:01 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | PurchaseCommon Stock | 600 | $35.33 | $21,197.94 |
DisclosureSEC source: 0000920465-17-000035 · wf-form4_148883408805069.xml · nonDerivative · entry 1 Chawla Lakhmir S · CIK 0001646626 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,085 Read SEC document |
| January 04, 2017 Filed Jan 6, 2017 18:23 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantStock Option (Right to Buy) · Derivative | 64,100 | $0.00 Strike: $19.19 | $0.00 |
DisclosureSEC source: 0000920465-17-000018 · wf-form4_148374501098440.xml · derivative · entry 1 Chawla Lakhmir S · CIK 0001646626 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,100 Underlying: Common Stock · 64,100 shares Expires 2027-01-04 F1 · derivative.exercise_date: This option represents a right to purchase a total of 64,100 shares of the Issuer's Common Stock one quarter of which shall be fully vested and exercisable on January 4, 2018, with the remaining 48,075 shares vesting monthly thereafter over the next three years. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.